Biotheus Collaborates with BioNTech for the Development and Commercialization of PM8002 to Treat Multiple Solid Tumor Indications
Shots:
- As per the agreement, Biotheus will receive an up front payment of $55M & is eligible to receive an aggregate of $1B in development, regulatory & sales-based milestone payments, plus tiered royalties. The transaction is expected to close by Q4’23
- In return, BioNTech has received the license to develop, manufacture & commercialize PM8002 globally, except Greater China for which Biotheus retains the rights. Additionally, PM8002 is currently being evaluated in a P-II trial as monotx. or in combination with CT in patients with advanced solid tumors
- PM8002 is a bispecific Ab that contains humanized anti-PD-L1 single heavy-chain variable (VHH) domains fused to an anti-VEGF-A IgG1 Ab containing Fc-silencing mutations
Ref: PRNewswire | Image: Biotheus
Related News:- Biotheus Entered into a License and Collaboration Agreement with Hansoh Pharma for PM1080
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
